VYNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vyne Therapeutics Inc (VYNE) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown revenue growth in the latest quarter, its significant net income loss and declining EPS are concerning. The technical indicators suggest a neutral trend with no strong buy signals, and there are no recent news or catalysts to drive the stock upward. Given the lack of clear positive momentum and the investor's preference for long-term stability, holding off on this stock is recommended.
The MACD histogram is positive and expanding, indicating slight bullish momentum. However, the RSI is in the neutral zone, and moving averages are converging, showing no clear trend. The stock is trading near its resistance levels (R1: 0.597, R2: 0.61), suggesting limited immediate upside potential.
Revenue increased by 39.67% YoY in the latest quarter, indicating some growth potential.
Net income dropped by 40.12% YoY, and EPS declined by 41.38% YoY, reflecting poor profitability. No recent news or significant trading trends from insiders or hedge funds.
In Q3 2025, revenue increased to $169,000 (up 39.67% YoY), but net income dropped to -$7,280,000 (down 40.12% YoY), and EPS declined to -0.17 (down 41.38% YoY). Gross margin remained flat at 100%.
No data available on analyst ratings or price target changes.
